Su1239 Mucosal Healing by Individual Anti TNF Agent in Crohn's Disease in Tertiary Care Setting

Zainab Ashir; Corinne Guilday; Yelena Zadvornova; Dan Joseph Stein; Amar S. Naik; Nanda Venu; Kari Best; Susan Skaros; Kia Saeian; Lilani P. Perera

doi:10.1016/s0016-5085(13)61606-6

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2012

Sa1229 Infliximab as Second Anti-TNF Agent in Crohn's Disease: Durability and Tolerance of Therapy

Jason E. Gonzaga, Yelena Zadvornova, Dan Joseph Stein, Lilani P. Perera, Amar S. Naik, Nanda Venu

Article2017

Mucosal Healing Rates in Patients with Upper Gastrointestinal Tract Crohn's Disease

Hasan Bader, Alexandra N. Modiri, Yelena Zadvornova, Dan Joseph Stein

Article2012

Sa1910 Long Term Outcomes of Crohn's Disease Patients on Maintenance Anti-TNF-α Therapy

Lilani P. Perera, Yelena Zadvornova, David G. Binion, Corinne Guilday, Dan Joseph Stein, Amar S. Naik, Nanda Venu, Kari Best, Susan Skaros

Article2025

Possible Involvement of the Mucosal Claudin Expression in the Healing of a Refractory Ileocecal Ulcer in a Patient with Crohn's Disease Successfully Treated with Infliximab

Sho Masaki, Yasuhiro Masuta, Yasuo Otsuka, Hajime Honjo, Tomoya Watanabe, Masatoshi Kudo

Article2019

P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study

Brian Bressler, Gerassimos J. Mantzaris, Mark S. Silverberg, Petros Zezos, Dan Joseph Stein, Chris Colby, T Lissoos, C. Lopez, Athanasios Natsios, Gabriela Radulescu, Haridarshan Patel, Dirk Demuth, Andrés Yarur